Histidine decarboxylase promotes acquired cisplatin resistance in gastric cancer cells

BACKGROUNDCisplatin-based chemotherapy is widely used in gastric cancer (GC), but acquired resistance substantially compromises treatment outcomes.Metabolic reprogramming plays an important role in cisplatin resistance in GC.Although histidine metabolism dysregulation has been reported in various cancers, the function of histidine decarboxylase (HDC) in modulating this process remains unclear. AIMTo characterize the key histidine-metabolizing enzyme involved in cisplatin resistance, discover the resistance mechanisms, and identify potential therapeutic targets in GC. METHODSCisplatin-resistant AGS/DDP and HGC-27/DDP cells were constructed, and tandem mass tag-based quantitative proteomic techniques combined with liquid chromatographytandem mass spectrometry were applied to screen and evaluate differentially expressed metabolism-related genes (fold-change > 1.2, P < 0.05).Cellular functional assays, including small interfering RNA knockdown, Western blotting, Cell Counting Kit-8 drug-sensitivity assays, and flow cytometric apoptosis assays, as well as tissue microarray analysis and immunohistochemistry, were performed to evaluate the association between differentially expressed proteins (DEPs) and cisplatin resistance in GC. RESULTSDEPs in cisplatin-resistant cells were enriched in histidine metabolism, oxidative phosphorylation, and fatty acid metabolism.Knockdown or pharmacological inhibition 4 / 34 of HDC reversed cisplatin resistance in resistant cells.The gene was abnormally upregulated in GC tissues and implied a poor prognosis. CONCLUSIONThis study highlights the role of histidine metabolism in cisplatin resistance in GC.Targeting HDC may be a promising therapeutic strategy for cisplatin-resistant GC, while also providing insight into the mechanism of resistance and potential therapeutic targets.

Authors

Institutions

Publication Details

Journal
World Journal of Gastroenterology
Published
2026-11-16
DOI
https://doi.org/10.3748/wjg.124512
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Histidine decarboxylase promotes acquired cisplatin resistance in gastric cancer cells

Yi-Ping Wang, Jing Han, Lian-Lian Hong, Hang Lv
1 links
World Journal of Gastroenterology
Gastric Cancer Management and Outcomes
article

Histidine decarboxylase promotes acquired cisplatin resistance in gastric cancer cells

Yi-Ping Wang, Jing Han, Lian-Lian Hong, Hang Lv
article en

Abstract

BACKGROUNDCisplatin-based chemotherapy is widely used in gastric cancer (GC), but acquired resistance substantially compromises treatment outcomes.Metabolic reprogramming plays an important role in cisplatin resistance in GC.Although histidine metabolism dysregulation has been reported in various cancers, the function of histidine decarboxylase (HDC) in modulating this process remains unclear. AIMTo characterize the key histidine-metabolizing enzyme involved in cisplatin resistance, discover the resistance mechanisms, and identify potential therapeutic targets in GC. METHODSCisplatin-resistant AGS/DDP and HGC-27/DDP cells were constructed, and tandem mass tag-based quantitative proteomic techniques combined with liquid chromatographytandem mass spectrometry were applied to screen and evaluate differentially expressed metabolism-related genes (fold-change > 1.2, P < 0.05).Cellular functional assays, including small interfering RNA knockdown, Western blotting, Cell Counting Kit-8 drug-sensitivity assays, and flow cytometric apoptosis assays, as well as tissue microarray analysis and immunohistochemistry, were performed to evaluate the association between differentially expressed proteins (DEPs) and cisplatin resistance in GC. RESULTSDEPs in cisplatin-resistant cells were enriched in histidine metabolism, oxidative phosphorylation, and fatty acid metabolism.Knockdown or pharmacological inhibition 4 / 34 of HDC reversed cisplatin resistance in resistant cells.The gene was abnormally upregulated in GC tissues and implied a poor prognosis. CONCLUSIONThis study highlights the role of histidine metabolism in cisplatin resistance in GC.Targeting HDC may be a promising therapeutic strategy for cisplatin-resistant GC, while also providing insight into the mechanism of resistance and potential therapeutic targets.

World Journal of Gastroenterology
Zhejiang Chinese Medical University (CN), Zhejiang Cancer Hospital (CN)
National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province
Good health and well-being
Gastric Cancer Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon